Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00008372 · ClinicalTrials.gov registry record · Phase 2

Chloroquinoxaline Sulfonamide in Treating Patients With Small Cell Lung Cancer

A Phase 2 study of Lung Cancer, sponsored by City of Hope Medical Center.

Completed
Registry status
Phase 2
Development phase
3
Study locations

NCT00008372 is a Phase 2 study of Lung Cancer that has completed, run by City of Hope Medical Center. The trial reports 3 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00008372, a Phase 2 study of Lung Cancer, has completed, sponsored by City of Hope Medical Center.

COMPLETED
Registry status
Phase 2
Development phase
3
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of chloroquinoxaline sulfonamide in treating patients who have small cell lung cancer that has not responded to platinum-based chemotherapy.

Conditions Studied

Interventions

  • DRUG chloroquinoxaline sulfonamide

Study Locations (3)

California

  • Cancer Center and Beckman Research Institute, City of Hope - Duarte
  • USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
  • University of California Davis Cancer Center - Sacramento

Trial Details

FieldValue
Start Date 2000-12
Est. Completion 2002-09
Phase Phase 2

Sponsor

City of Hope Medical Center

582 total trials

What the Registry Record Tells You About NCT00008372

The ClinicalTrials.gov registry entry for NCT00008372 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which chloroquinoxaline sulfonamide is the first listed.

NCT00008372 reports 3 study locations spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT00008372 about?

NCT00008372 is a clinical study titled "Chloroquinoxaline Sulfonamide in Treating Patients With Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of chloroquinoxaline sulfonamide in treating patients who have small cell lung cancer that has not responded to platinum-based c...

What is the current status of trial NCT00008372?

This trial is currently completed. It is a Phase 2 study. The study started on 2000-12. Estimated completion is 2002-09.

What conditions does trial NCT00008372 study?

This clinical trial studies the following conditions: Lung Cancer.

What interventions are being tested in trial NCT00008372?

The interventions under investigation include: chloroquinoxaline sulfonamide (DRUG).

Who is sponsoring clinical trial NCT00008372?

This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00008372 being conducted?

This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.